SK bioscience Co.,Ltd. (KRX:302440)

Market Cap	3.35T -8.0%
Revenue (ttm)	651.37B +143.5%
Net Income	-57.42B
EPS	-733.00
Shares Out	78.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,563
Average Volume	145,090
Open	42,000
Previous Close	42,650
Day's Range	41,500 - 42,550
52-Week Range	35,800 - 61,300
Beta	1.06
RSI	42.55
Earnings Date	Apr 28, 2026

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 917
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 302440

Financial Performance

In 2025, SK bioscience's revenue was 651.37 billion, an increase of 143.46% compared to the previous year's 267.55 billion. Losses were -57.42 billion, 6.58% more than in 2024.